Kaléo's EpiPen competitor to return to US market

27 October 2016

Kaléo, a privately-held US pharmaceutical company, has said it will reintroduce Auvi-Q (epinephrine injection, USP) auto-injector to the US market in the first half of 2017.

Auvi-Q is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions, which was previously marketed for Kaléo by Sanofi, but was pulled in late 2015 due to problems with the injection mechanism.

Auvi-Q will again compete with the EpiPen Auto-Injector (epinephrine injection, USP) from Mylan (Nasdaq: MYL), which has suffered a barrage of criticism and congressional investigations for its exorbitant pricing. Mylan itself has said it will bring a generic version to the US market at a list price of $300 per generic EpiPen two-pack carton. This represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost (WAC), of the branded medicine. Mylan’s shares were off 1.55% at $38.08 by close of trading yesterday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK